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Abstract
Purpose Our aim was to investigate whether serum and
synovial-fluid (SF) concentrations of interleukin-6 (IL-6), lep-
tin, adiponectin, resistin or visfatin are associated with joint
pain in hip and knee in end-stage osteoarthritis (OA).
Methods A cross-sectional study assessing patients with hip
and knee OA undergoing total joint arthroplasty between
January and December 2010 was conducted at a large univer-
sity hospital. Serum and SF cytokine and adipokine concen-
trations were determined in samples obtained on the day of
surgery. The main outcome was pain severity measured
pre-operatively using the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) and visual ana-
logue scale (VAS) pain scores.
Results A total of 206 patients were involved (112 with hip
and 94 with knee OA). Median age was 72 years [interquartile
range (IQR) 66–79], 59 % were women. All adipokine levels
were significantly higher in the SF of hip joints than in that of
knee joints, except for leptin, which tended to be higher in the
knee. In both hip and knee OA, median serum concentrations
of leptin, adiponectin, resistin and visfatin exceeded those in
SF, whereas for IL-6, median concentrations were much
higher in SF than in serum. In hip OA, worse pain was
significantly associated with high SF concentrations of IL-6,
visfatin and leptin; in knee OA, it was associated with high SF
leptin and low SF adiponectin concentrations and a low
adiponectin–leptin ratio.
Conclusion Our findings support a connection between intra-
articular concentrations of several adipokines and severity of
preoperative OA pain. However, the specific adipokines dif-
fered by joints: in hip OA, pain was associated with IL-6 and
visfatin and in knee OAwith adiponectin; leptin played a role
in both hip and knee OA.
Keywords Adipokine . Osteoarthritis . Pain . Visfatin .
Leptin
Introduction
Joint pain is the major clinical feature of osteoarthritis (OA), a
disease caused bymultiple and yet non completely understood
pathways [23]. Adipokines, such as interleukin-6 (IL-6), lep-
tin, adiponectin, resistin and visfatin, belong to the family of
white-adipose-tissue-produced factors involved in modulating
immune and inflammatory responses [10, 27] and are present
in synovial fluid (SF) of patients with OA [5, 8, 11, 13, 19,
22]. Very few studies have investigated the relationship be-
tween these adipokines and patient-reported joint pain [9, 14,
15]. Gandhi et al. reported that SF adiponectin–leptin ratio
predicted pain in knee OA [9]. Massengale et al. [15] found
that leptin serum concentration was associated with pain in-
tensity in patients with chronic hand OA. Moreover, we
recently found that leptin levels correlated with pain in end-
stage OA [14]. To our knowledge, no clinical study thus far
has evaluated a possible relationship between other
adipokines, such as visfatin and resistin, and hip or knee OA
pain. Visfatin has proinflammatory and immunomodulating
functions, including the increase of tumour necrosis factor-
alpha (TNF-α), IL-1β, IL-6 and monocyte chemoattractant
protein-1 (MCP-1) production and activation of B cells, T
cells and monocytes [1, 17, 21, 25, 26]. Recently, visfatin
involvement was suggested in the pathogenesis of OA pain
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[18]. Little is known about resistin and OA [15]. One study
reported a higher serum resistin concentration in OA patients
compared with healthy controls, as well as a weak positive
association between histological grade of synovial inflamma-
tion and resistin concentration [7].
The objectives of this exploratory study were to determine
whether SF or serum adipokine concentrations are related to
pain in patients with end-stage hip or knee OA, and whether
adipokine concentrations and their relationship with pain
might differ between joints.
Materials and methods
Study design and patient population
We conducted a cross-sectional study of patients with end-
stage hip or knee OAwho presented for total joint arthroplasty
(TJA) at a large orthopaedic centre between January and
December 2010. Part of the following method’s section has
already been described in a previous publication on the same
cohort [14]. Patients with secondary OA due to trauma or
inflammatory arthritis were excluded. The study was ap-
proved by the local ethics committee and informed consent
was obtained from all patients.
Cytokine measurement
SF (1 ml) was collected during surgery by the operating
surgeon via direct aspiration through the joint capsule imme-
diately after skin incision to minimise blood contamination.
Because we only included elective TJA, they were all per-
formed in the morning and early afternoon. Blood samples
(5 ml) were obtained in the morning during the pre-operative
examination at the same time as standard pre-operative blood
specimens were obtained. All blood and SF samples were
immediately centrifuged. Serum and SF were aliquoted and
frozen at −80 °C until measurement. DuoSet enzyme-linked
immunosorbent assay (ELISA) (R&D Systems, Abingdon,
UK) were used to determine IL-6, leptin, adiponectin and
resistin concentrations according to the manufacturer. Mini-
mum detectable cytokine concentrations for these assays was
estimated to be 9.4 pg/ml for IL-6, 31.2 pg/ml for leptin,
62.5 pg/ml for adiponectin and 31.2 pg/ml for resistin. Both
intra- and interassay coefficients of variation were < 10 %.
Visfatin concentrations were measured using a Phoenix
ELISA kit (Phoenix Pharmaceuticals, Inc., Burlingame, CA,
USA) according to the manufacturer. The estimated minimum
detectable visfatin concentration was 2.2 ng/ml (interassay
variation <15 % and intraassay variation <10 %). In addition,
the adiponectin–leptin ratio was calculated to allow for com-
parison with a previous study [9].
Outcome assessment
The main outcome was the pre-operative pain level measured
with the Western Ontario and McMaster Universities Osteo-
arthritis Index (WOMAC) pain score [2]. The score was
analysed both as continuous (0–100, 100=no pain) and as
dichotomised (>25 vs. ≤25=quartile with greatest pain) vari-
able; visual analog scale (VAS) for pain assessment evaluated
as continuous variable (0–10, 0=no pain). Scores were sent to
all patients seven to ten days prior to surgery. A medical
secretary was involved in sending and collecting scores and
questionnaires and in data entry. Baseline characteristics were
obtained preoperatively at the entrance examination.
Statistical analysis
The patterns of adipokine distribution between synovial and
blood compartments were studied according to OA site. The
Mann–Whitney U test was used to compare concentrations
between hip and knee OA groups, and Spearman’s correlation
coefficients were calculated to assess correlations between the
two compartments. The association between SF concentra-
tions and pain was evaluated as continuous variable using
Spearman’s correlation coefficient and as categorical variable
using quartiles. Relative risks (RR) and their 95 % confidence
intervals (CI) were calculated to compare proportions of pa-
tients with the highest pain level among those in the highest
quartile of adipokine concentration vs. first to third quartiles.
Logist ic regression analysis with WOMAC pain
dichotomised as dependent variable was used to adjust for
sex, body mass index (BMI) and smoking.
Results
A total of 206 patients with complete SF analysis and pain
evaluation were assessed: 112 with hip and 94 with knee OA.
The group with hip OA comprised 58 women (51.8 %) with a
median age of 72 years [interquartile range (IQR) 66–78) and
a median BMI 27 kg/m2 (IQR 24–29.6); 23 % were obese.
Regarding medical comorbidities: 39.3 % were ever-smokers,
9.8 % had diabetes, 61.6 % had hypertension and 8 % had
cardiac disease. The group with knee OA comprised 64 wom-
en (68.1 %), median age was 74.5 years (IQR 68–79.3) and
median BMI was 28.3 kg/m2 (IQR 25.4–31.2); 33 % were
obese. Regarding medical comorbidities, 26.1 % were ever-
smokers, 13.8 % had diabetes, 64.9 % had hypertension and
4.3 % had cardiac disease. Of the 206 patients, 186 (90.3 %)
also had serum analyses available: 109 with hip and 77 with
knee OA.
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Adipokine concentrations according to OA site
All adipokine levels were significantly higher in the SF of hip
joints than in the SF of knee joints, except for leptin, which
tended to be higher in the knee (Table 1). In serum, hip OA
patients had significantly higher IL-6 concentrations, and knee
OA patients had significantly higher leptin concentrations; the
level of the other adipokines did not differ according to OA
site. Median serum concentrations of leptin, adiponectin,
resistin and visfatin exceeded those in SF, whereas for IL-6,
median concentrations were much higher in SF (hip 279.0 vs.
1.3 pg/ml; knee 22.7 vs. 0.7 pg/ml).
Correlation between serum and SF adipokine concentrations
Leptin and adiponectin concentrations were highly correlated
in serum and SF both in hip and knee OA (Table 1). There was
a weak correlation for resistin, and no significant correlation
was observed for visfatin. Serum and SF IL-6 concentrations
were significantly (weakly) correlated only in patients with
hip OA.
Association between SF adipokine concentrations
and pre-operative pain
In patients with hip OA, worse pain scores were significantly
correlated with increased SF IL-6 and visfatin concentrations
(Table 2). In contrast, in patients with knee OA, worse pain
scores were significantly correlated with increased SF leptin
concentrations and decreased SF adiponectin–leptin ratio. In
serum, only SF leptin concentrations in the knee OA group
were linearly correlated with pain.
In hip OA, patients with the highest degree of pain
(WOMAC score ≤25) had more often significantly higher
concentrations of SF IL-6 (fourth quartile vs. first to third:
RR 2.2; 95 % CI 1.2-3.8), visfatin (RR 2.4; 95 % CI 1.4-4.2)
and leptin (RR 2.4; 95 % CI 1.5-4.0), (Fig. 1). In knee OA,
patients with the highest degree of pain had more often sig-
nificantly high SF leptin (RR 2.7; 95 % CI 1.3-5.8) concen-
trations and linearly decreased SF adiponectin concentrations
(in quartiles, p for trend 0.013). The relationship remained
significant for SF visfatin and leptin in hip and for SF leptin in
knee OA after adjusting for BMI, sex and smoking.
Discussion
Our findings support a differential relationship between intra-
articular concentrations of several adipokines and preopera-
tive pain for hip and knee OA. They further demonstrate
differential adipokine levels by joints, with higher levels of
SF IL-6, adiponectin, resistin and visfatin in hip than in knee
OA, and higher SF leptin concentration in knee OA compared
with hip OA. The observed differences are in agreement with
the established notion that hip OA stands out as a different
Table 2 Correlation between synovial fluid (SF) adipokine concentrations, body mass index (BMI) and pain
Leptin Adiponectin Resistin Visfatin BMI VAS pain WOMAC pain
Hip (n=112)
IL-6 0.342** 0.095 −0.038 0.296** 0.082 0.275** −0.338**
Leptin 0.084 −0.021 0.139 0.435** 0.116 −0.163
Adiponectin 0.235* 0.258** −0.051 0.159 −0.116
Adiponectin–leptin ratio −0.335** 0.034 0.026
Resistin 0.297** 0.102 0.001 0.062
Visfatin 0.073 0.242* −0.279**
Knee (n=94)
IL-6 0.124 0.14 0.071 −0.052 −0.093 0.057 0.032
Leptin 0.208* 0.056 0.153 0.575** 0.194 −0.258*
Adiponectin 0.153 0.220* 0.056 −0.096 0.184
Adiponectin–leptin ratio −0.414** −0.195 0.293**
Resistin 0.123 0.093 −0.096 0.047
Visfatin 0.16 0.101 0.054
Spearman’s correlation coefficients
IL interleukin, VAS visual analogue scale, WOMACWestern Ontario and McMaster Universities Osteoarthritis Index
*Significant at 0.05
**Significant at 0.01
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Fig. 1 a–e Proportion with highest Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) pain level (≤25) according to quartiles of
synovial fluid (SF) adipokine concentrations
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entity. It often occurs alone, at a younger age, in a higher
proportion of men and with a different set of risk factors [6].
The associations of SF IL-6 and visfatin with pain in hip
OA have not been reported so far. Our results corroborate
previous clinical studies reporting an association between IL-6
levels and chronic low back pain [12] and between visfatin
levels and pain in incipient upper-extremity soft-tissue disor-
ders [20]. Interestingly, a recent experimental study suggested
involvement of visfatin in the pathogenesis of OA pain via
induction of nerve growth factor (NGF) release [18]. Other
experimental studies using human adipocytes [25] and human
endothelial cells [1] showed that visfatin stimulated in a dose-
dependent fashion the production of MCP-1, a chemokine
regulating migration and infiltration of monocytes/
macrophages, which has recently been reported to mediate
pain in experimental OA [16]. Regarding IL-6 and its influ-
ence on pain, an experimental study on rats [4] found an
association between IL-6 and increased mechanical hypersen-
sitivity, possibly through an action of the cytokine on nerve
fibres. SF IL-6 and visfatin concentrations were correlated in
hip OA patients in our study, confirming the findings of
Moschen et al. of a strong correlation between visfatin and
markers of inflammation, such as IL-6 [17].
We previously demonstrated a positive association be-
tween SF leptin and increased pain in patients with hip and
knee OA [14]. Moreover, in knee OA patients, adiponectin
and adiponectin–leptin ratio were correlated with pain, a find-
ing in accordance with Gandhi et al. [9]. No correlation
between resistin and OA pain in hip or knee was found, a
finding also reported by Massengale et al. in their study on
adipokines and pain in hand OA [15].
So far, clinical studies on the relationship between
adipokines and pain in OA are limited by small samples,
no stratification of adipokine concentrations by OA joints
or a limited number of adipokines examined. The study
reported here involved a large number of patients for whom
concentrations of five different adipokines were determined
in hip and knee SF and serum, all at the same time.
Nevertheless, our study is limited by its cross-sectional
design, precluding evaluation of causal relationships. More-
over, adipokines show diurnal variations [3, 24], and we
cannot exclude that this factor may have partly influenced
our results regarding SF concentrations, which were obtain-
ed during a time span ranging from morning to early
afternoon.
In conclusion, our findings support a connection between
intra-articular concentrations of several adipokines and sever-
ity of preoperative pain, which differs between patients with
hip and knee OA. In hip OA, pain was associated with IL-6
and visfatin. In knee OA, pain was associated with
adiponectin, whereas leptin played a role in both hips and
knees. These results may help further characterise different
OA phenotypes and better target pain treatment.
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